Gregory Bannish

Title: Gregory Bannish: Innovator in Hybridoma Technology

Introduction

Gregory Bannish is a notable inventor based in Morton, PA (US), recognized for his contributions to the field of biotechnology. He holds two patents that focus on enhancing the efficiency of hybridoma fusion and altering protein production rates. His work has significant implications for the production of antibodies, which are crucial for therapeutic and diagnostic applications.

Latest Patents

Bannish's latest patents include "Enhancement of hybridoma fusion efficiencies through cell synchronization," which provides methods to improve fusion efficiencies of hybridoma cells. This innovation aids in the production of antibodies by synchronizing the fusion partners. Another patent, "Methods for altering protein production rates," discloses techniques for modifying the cellular secretion rate of proteins, such as antibodies. The methods and altered cells produced by this invention are valuable for generating high levels of proteins for various purposes, including therapeutic and research applications.

Career Highlights

Throughout his career, Bannish has worked with prominent companies in the biotechnology sector, including Centocor, Inc. and Centocor Ortho Biotech Inc. His experience in these organizations has contributed to his expertise in hybridoma technology and protein production.

Collaborations

Bannish has collaborated with several professionals in his field, including Michael Rycyzyn and Jill M. Giles-Komar. These collaborations have likely enriched his research and development efforts.

Conclusion

Gregory Bannish's innovative work in hybridoma technology and protein production exemplifies the impact of inventors in advancing biotechnology. His patents reflect a commitment to enhancing methods that are essential for the development of therapeutic antibodies.